Sec Form 4 Filing - Huang Qingxi @ US-China Biomedical Technology, Inc. - 2019-05-29

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Huang Qingxi 2. Issuer Name and Ticker or Trading Symbol US-China Biomedical Technology, Inc. [ UCBB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO, CFO, Secy., Treas. (Last) (First) (Middle) 21F, HUALING BUILDING, 111 FURONG RD, CHANGSHA 3. Date of Earliest Transaction (MM/DD/YY) 05/29/2019 (Street) HUNAN PROVINCE, CHINA, F4410000 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/29/2019 P 4,290,000 A $ 214,500 12,422,000 I See footnote ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant $ 0.05 05/29/2019 P 10,725,000 05/24/2019 11/24/2020 Common Stock 10,725,000 $ 0.05 10,725,000 I See footnote ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Huang Qingxi 21F, HUALING BUILDING 111 FURONG RD, CHANGSHA HUNAN PROVINCE, CHINA, F4410000 X X CEO, CFO, Secy., Treas. Signatures /s/ Qingxi Huang 07/05/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On May 29, 2019, China Israel Biotechnology Co. Ltd. ("CIB"), a Chinese corporation, of which Mr. Huang is a controlling officer and director of, acquired 4,290,000 units at purchase price of $0.05 per share. Each single Unit consists of one (1) share of common stock of the Company and two and one half (2.5) warrants (collectively the "Units"), which shall be exercisable for 18 months at $0.05 per share (the "Warrants"). ( 2 )Mr. Huangs beneficial ownership includes 10,922,000 shares held by CIB and 1,500,000 shares held by Central Bio-MD Valley Technology Co., Ltd. ("CBV"), a Chinese corporation. Mr. Huang is a controlling officer and director of CIB and CBV and has voting and dispositive control over the shares.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.